Values as of: 2024-09-18
COMMON STOCK | Medical Distribution |
Last Closing
USD 3.08Change
-0.07 (-2.22)%Market Cap
USD 0.12BVolume
0.02MAnalyst Target
USD 5.29Verdict
Verdict
EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. The company operates through High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST) segments. The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment also offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology; and offers Sonolith i-move, an extracorporeal shockwave lithotripter, as well as sells disposable parts for lithotripters and electrodes. The Distribution division markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. It markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. The company serves hospitals, urology clinics, and research institutions. EDAP TMS S.A. was incorporated in 1979 and is based in Lyon, France.
Company Website : https://www.edap-tms.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| HSIC | Henry Schein Inc |
+1.22 (+1.71%) |
USD 8.92B |
| PDCO | Patterson Companies Inc |
+0.22 (+1.01%) |
USD 1.93B |
| AHG | Akso Health Group ADR |
+0.15 (+15.82%) |
USD 0.22B |
| YI | 111 Inc |
-0.05 (-7.69%) |
USD 0.05B |
| COSM | Cosmos Health Inc. |
-0.03 (-2.63%) |
N/A |
| ZYXI | Zynex Inc |
-0.01 (-0.12%) |
N/A |
N/A
| Market Performance vs. Industry/Classification (Medical Distribution) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -41.67% | 29% | F | 19% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -41.67% | 29% | F | 19% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | -53.40% | 29% | F | 17% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -53.40% | 29% | F | 17% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | -31.86% | 50% | F | 33% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -31.86% | 50% | F | 31% | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 31.26% | 86% | B+ | 84% | B | ||
| Dividend Return | 31.26% | 86% | B+ | 84% | B | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 75.37% | 43% | F | 24% | F | ||
| Risk Adjusted Return | 41.48% | 86% | B+ | 72% | C | ||
| Market Capitalization | 0.12B | 40% | F | 41% | F | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
The company had positive total free cash flow in the most recent four quarters.
The stock is trading high compared to its peers median on a price to book value basis.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
The company had negative total cash flow in the most recent four quarters.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
This stock has shown below median earnings growth in the previous 5 years compared to its sector
